title: Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
authors.affiliation: INSERM U836 équipe 7, Grenoble, France.
authors.forename: D
authors.initials: D
authors.lastname: Rolland
authors.forename: M
authors.initials: M
authors.lastname: Raharijaona
authors.forename: A
authors.initials: A
authors.lastname: Barbarat
authors.forename: R
authors.initials: R
authors.lastname: Houlgatte
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001897:Boronic Acids / Q000008:administration & dosage / Q000494:pharmacology; D000069286:Bortezomib; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D051549:Glutathione S-Transferase pi / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D037102:Lectins / Q000008:administration & dosage / Q000494:pharmacology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology; D000093542:Gemcitabine
chemical_list: C041433:Agaricus lectins; D000970:Antineoplastic Agents; D001897:Boronic Acids; D037102:Lectins; D011719:Pyrazines; D003561:Cytarabine; D003841:Deoxycytidine; D000069286:Bortezomib; D004317:Doxorubicin; C496556:GSTP1 protein, human; D051549:Glutathione S-Transferase pi; D002945:Cisplatin; D000093542:Gemcitabine